Rhodanine as a scaffold in drug discovery: A critical review of its biological activities and mechanisms of target modulation

Expert Opinion on Drug Discovery

Volumn 7, Issue 7, 2012, Pages 549-560

  Tomašić, Tihomir ^a   Peterlin Mašič, Lucija ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

HTS; Privileged; Promiscuous; Rhodanine; Scaffold

Indexed keywords

RHODANINE;

ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ANALYSIS; ENZYME SPECIFICITY; HIGH THROUGHPUT SCREENING; HUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; RHODANINE; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINEDIONES;

EID: 84862859338     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.688743     Document Type: Review

References (64)

1. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010;53:2719-40
2. Baell JB. Observations on screening-based research and some concerning trends in the literature. Future Med Chem 2010;2:1529-46
3. Mendgen T, Steuer C, Klein CD. Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. J Med Chem 2012;55:743-53
4. Tomasic T, Masic LP. Rhodanine as privileged scaffold in drug discovery. Curr Med Chem 2009;16:1596-629
5. Terashima H, Hama K, Yamamoto R, et al. Effects of a new aldose reductase inhibitor on various tissues in vitro. J Pharmacol Exp Ther 1984;229:226-30 (Pubitemid 14082937)
6. Chen ZH, Zheng CJ, Sun LP, Piao HR. Synthesis of new chalcone derivatives containing a rhodanine-3-acetic acid moiety with potential anti-bacterial activity. Eur J Med Chem 2010;45:5739-43
7. Hardej D, Ashby CR Jr, Khadtare NS, et al. The synthesis of phenylalanine-derived C5-substituted rhodanines and their activity against selected methicillin-resistant Staphylococcus aureus (MRSA) strains. Eur J Med Chem 2010;45:5827-32
8. Tomasic T, Zidar N, Mueller-Premru M, et al. Synthesis and antibacterial activity of 5-ylidenethiazolidin-4-ones and 5-benzylidene-4,6-pyrimidinediones. Eur J Med Chem 2010;45:1667-72
9. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011;24:71-109
10. Aiello D, Barnes MH, Biswas EE, et al. Discovery, characterization and comparison of inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicases. Bioorg Med Chem 2009;17:4466-76
11. Tomasic T, Zidar N, Rupnik V, et al. Synthesis and biological evaluation of new glutamic acid-based inhibitors of MurD ligase. Bioorg Med Chem Lett 2009;19:153-7
12. Zidar N, Tomasic T, Sink R, et al. Discovery of novel 5-benzylidenerhodanine and 5- benzylidenethiazolidine-2,4-dione inhibitors of MurD ligase. J Med Chem 2010;53:6584-94
13. Zidar N, Tomasic T, Sink R, et al. New 5-benzylidenethiazolidin-4-one inhibitors of bacterial MurD ligase: design, synthesis, crystal structures, and biological evaluation. Eur J Med Chem 2011;46:5512-23
14. Tomasic T, Zidar N, Sink R, et al. Structure-based design of a new series of D-glutamic acid based inhibitors of bacterial UDP-N-acetylmuramoyl-Lalanine: D-glutamate ligase (MurD). J Med Chem 2011;54:4600-10
15. Tomasic T, Zidar N, Kovac A, et al. 5-Benzylidenethiazolidin-4-ones as multitarget inhibitors of bacterial Mur ligases. ChemMedChem 2010;5:286-95
16. Tomasic T, Kovac A, Simcic M, et al. Novel 2-thioxothiazolidin-4-one inhibitors of bacterial MurD ligase targeting D-Glu- and diphosphate-binding sites. Eur J Med Chem 2011;46:3964-75
17. Suree N, Yi SW, Thieu W, et al. Discovery and structure-activity relationship analysis of Staphylococcus aureus sortase A inhibitors. Bioorg Med Chem 2009;17:7174-85
18. Beuria TK, Singh P, Surolia A, Panda D. Promoting assembly and bundling of FtsZ as a strategy to inhibit bacterial cell division: a new approach for developing novel antibacterial drugs. Biochem J 2009;423:61-9
19. Talele TT, Arora P, Kulkarni SS, et al. Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase. Bioorg Med Chem 2010;18:4630-8
20. Katritzky AR, Tala SR, Lu H, et al. Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3- phenethyl-2- thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors. J Med Chem 2009;52:7631-9
21. He XY, Zou P, Qiu J, et al. Design, synthesis and biological evaluation of 3-substituted 2,5-dimethyl-N-(3-(1Htetrazol- 5-yl)phenyl)pyrroles as novel potential HIV-1 gp41 inhibitors. Bioorg Med Chem 2011;19:6726-34
22. Maga G, Falchi F, Radi M, et al. Toward the discovery of novel anti-HIV drugs. Second-generation inhibitors of the cellular ATPase DDX3 with improved anti-HIV activity: synthesis, structure-activity relationship analysis, cytotoxicity studies, and target validation. ChemMedChem 2011;6:1371-89
23. Havrylyuk D, Mosula L, Zimenkovsky B, et al. Synthesis and anticancer activity evaluation of 4-thiazolidinones containing benzothiazole moiety. Eur J Med Chem 2010;45:5012-21
24. Moorthy BT, Ravi S, Srivastava M, et al. Novel rhodanine derivatives induce growth inhibition followed by apoptosis. Bioorg Med Chem Lett 2010;20:6297-301
25. Li W, Zhai X, Zhong Z, et al. Design, synthesis and evaluation of novel rhodanine-containing sorafenib analogs as potential antitumor agents. Arch Pharm 2011;344:349-57
26. Bernardo PH, Sivaraman T, Wan KF, et al. Structural insights into the design of small molecule inhibitors thatselectively antagonize Mcl-1. J Med Chem 2010;53:2314-18
27. Lugovskoy AA, Degterev AI, Fahmy AF, et al. A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors. J Am Chem Soc 2002;124:1234-40 (Pubitemid 34169130)
28. Park H, Jung SK, Yu KR, et al. Structure-based virtual screening approach to the discovery of novel inhibitors of eyes absent 2 phosphatase with various metal chelating moieties. Chem Biol Drug Des 2011;78:642-50
29. Harada K, Kubo H, Tanaka A, Nishioka K. Identification of oxazolidinediones and thiazolidinediones as potent 17beta-hydroxysteroid dehydrogenase type 3 inhibitors. Bioorg Med Chem Lett 2012;22:504-7
30. Strittmatter T, Bareth B, Immel TA, et al. Small molecule inhibitors of human DNA polymerase lambda. ACS Chem Biol 2011;6:314-19
31. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-99 (Pubitemid 44711953)
32. Heng S, Tieu W, Hautmann S, et al. New cholesterol esterase inhibitors based on rhodanine and thiazolidinedione scaffolds. Bioorg Med Chem 2011;19:7453-63
33. Carroll RT, Dluzen DE, Stinnett H, et al. Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B. Bioorg Med Chem Lett 2011;21:4798-803
34. Maccari R, Del Corso A, Giglio M, et al. In vitro evaluation of 5-arylidene-2- thioxo-4-thiazolidinones active as aldose reductase inhibitors. Bioorg Med Chem Lett 2011;21:200-3
35. La Pietra V, Marinelli L, Cosconati S, et al. Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization. Eur J Med Chem 2012;47:143-52
36. Kopeikin Z, Sohma Y, Li M, Hwang TC. On the mechanism of CFTR inhibition by a thiazolidinone derivative. J Gen Physiol 2010;136:659-71
37. Manuvakhova MS, Johnson GG, White MC, et al. Identification of novel small molecule activators of nuclear factor-kappaB with neuroprotective action via high-throughput screening. J Neurosci Res 2011;89:58-72
38. Lesyk RB, Zimenkovsky BS. 4-thiazolidones: centenarian history, current status and perspectives for modern organic and medicinal chemistry. Curr Org Chem 2004;8:1547-77 (Pubitemid 39381743)
39. Sink R, Gobec S, Pecar S, Zega A. False positives in the early stages of drug discovery. Curr Med Chem 2010;17:4231-55
40. Babaoglu K, Simeonov A, Irwin JJ, et al. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. J Med Chem 2008;51:2502-11 (Pubitemid 351628511)
41. McGovern SL, Caselli E, Grigorieff N, Shoichet BK. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 2002;45:1712-22 (Pubitemid 34293537)
42. McGovern SL, Helfand BT, Feng B, Shoichet BK. A specific mechanism of nonspecific inhibition. J Med Chem 2003;46:4265-72 (Pubitemid 37153008)
43. Powers JP, Piper DE, Li Y, et al. SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J Med Chem 2006;49:1034-46 (Pubitemid 43221651)
44. Carlson EE, May JF, Kiessling LL. Chemical probes of UDP-galactopyranose mutase. Chem Biol 2006;13:825-37 (Pubitemid 44247773)
45. Huth JR, Mendoza R, Olejniczak ET, et al. ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens. J Am Chem Soc 2005;127:217-24 (Pubitemid 40094385)
46. Huth JR, Song D, Mendoza RR, et al. Toxicological evaluation of thiol-reactive compounds identified using a La assay to detect reactive molecules by nuclear magnetic resonance. Chem Res Toxicol 2007;20:1752-9
47. Carter PH, Scherle PA, Muckelbauer JK, et al. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha. Proc Natl Acad Sci USA 2001;98:11879-84 (Pubitemid 32959795)
48. Forino M, Johnson S, Wong TY, et al. Efficient synthetic inhibitors of anthrax lethal factor. Proc Natl Acad Sci USA 2005;102:9499-504
49. Georgescu RE, Yurieva O, Kim SS, et al. Structure of a small-molecule inhibitor of a DNA polymerase sliding clamp. Proc Natl Acad Sci USA 2008;105:11116-21
50. Cerchietti LC, Ghetu AF, Zhu X, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010;17:400-11
51. Wu J, Tao Y, Zhang M, et al. Crystal structures of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoyl-CoA and inhibitors reveal the functional roles of the N-terminal region. J Biol Chem 2007;282:22185-94 (Pubitemid 47195743)
52. Grant EB, Guiadeen D, Baum EZ, et al. The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors. Bioorg Med Chem Lett 2000;10:2179-82
53. Villain-Guillot P, Gualtieri M, Bastide L, et al. Structure-activity relationships of Phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms. J Med Chem 2007;50:4195-204
54. Allen FH, Bird CM, Rowland RS, Raithby PR. Resonance-induced hydrogen bonding at sulfur acceptors in R1R2C=C and R1CS2- systems. Acta Crystallogr B 1997;53:680-95
55. Wood PA, Pidcock E, Allen FH. Interaction geometries and energies of hydrogen bonds to C = O and C = acceptors: a comparative study. Acta Crystallogr B 2008;64:491-6
56. Karanam BV, Hop CE, Liu DQ, et al. In vitro metabolism of MK-0767 [(+/-)- 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2- methoxy-N-[[(4-trifluoromethyl)phenyl] methyl]benzamide], a peroxisome proliferator-activated receptor alpha/ gamma agonist. I. Role of cytochrome P450, methyltransferases, flavin monooxygenases, and esterases. Drug Metab Dispos 2004;32:1015-22 (Pubitemid 39096063)
57. Reddy VB, Karanam BV, Gruber WL, et al. Mechanistic studies on the metabolic scission of thiazolidinedione derivatives to acyclic thiols. Chem Res Toxicol 2005;18:880-8 (Pubitemid 40705455)
58. Saha S, New LS, Ho HK, et al. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity. Toxicol Lett 2010;192:141-9
59. Mansuy D, Dansette PM. Sulfenic acids as reactive intermediates in xenobiotic metabolism. Arch Biochem Biophys 2011;507:174-85
60. Cutshall NS, O'Day C, Prezhdo M. Rhodanine derivatives as inhibitors of JSP-1. Bioorg Med Chem Lett 2005;15:3374-9 (Pubitemid 40835739)
61. French KJ, Schrecengost RS, Lee BD, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003;63:5962-9
62. Hu Y, Helm JS, Chen L, et al. Identification of selective inhibitors for the glycosyltransferase MurG via high-throughput screening. Chem Biol 2004;11:703-11 (Pubitemid 38708839)
63. Degterev A, Lugovskoy A, Cardone M, et al. Identification of small-molecule inhibitors of the interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001;3:173-82 (Pubitemid 32118371)
64. Pymol is available from Delano Scientific LLC, San Francisco, CA. Available from: http://pymol.sourceforge.net